Abstract:1550 Background: Immune checkpoint blockades (ICBs) have drastically improved the clinical outcomes of cancer patients, while only ~30% of them get significant benefits from immunotherapy. TMB, PD-L1, TNB, GEP (Cristescu et al. 2018) and other conventional biomarkers can explain only ~60% of the ICB response, suggesting that novel factors are yet to be discovered. Methods: Gene expression profiles and clinical information of 672 patients were collected from IMvigor210 (n=348, bladder cancer), Pender et al. (n=98, 20 tumor types), Kim et al. (n=45, gastric cancer) and CheckMate (n=181, kidney cancer) cohorts, in which all patients were treated with ICBs. In each sample, gene expression intensities normalized by RPKM were ranked in descender order (range of 1-20000) and scaled into the 0-1 range lastly. To identify immune signatures that correlated with both response and survival, 1000+ immune genes were downloaded from InnatDB database, and their expression values were compared between the two groups of IMvigor210 data which were divided according to response (CR+PR vs. SD+PD, Wilcoxon test) or overall survival (≥mOS vs. <mOS, Cox survival analysis). Bayesian-regularization neural networks (BRNN) model was used to develop the risk model to predict ICB response and prognosis. 75% of IMvigor210 data were randomly selected as the training set, and the remaining 25% as the test set. The performance of predictor was independently validated in Pender et al., Kim et al., and CheckMate cohorts subsequently. ROC curves were used to evaluate the predictive accuracy to response. Survival plots were created using the Kaplan-Meier estimator, and data were analyzed by log-rank test. Results: 40 DEGs (including top20 DEGs positively correlated with ORR/OS and top20 DEGs negatively correlated with ORR/OS) were identified as immune signatures, in which each gene signature could significantly distinguish ICB response and survival. Our model outperformed TMB or GEP in the prediction of response in IMvigor210 (Model = 0.986 vs. TMB = 0.728 vs. GEP = 0.551), Pender et al. (Model = 0.757 vs. TMB = 0.593 vs. GEP = 0.621), Kim et al. (Model = 0.881 vs. GEP = 0.828), and CheckMate (Model = 0.927 vs. TMB = 0.543) cohorts when AUC was used as performance metric. Meanwhile, our model showed promising results for differentiating longer survivors from shorter survivors with p vale <0.0001, 0.064, 0.021, and 0.0006 in IMvigor210, Pender et al., Kim et al., and CheckMate cohorts respectively. Conclusions: We proposed a deep learning model to predict ICB response and survival, in which feature selection based on immune gene expression order, allowing all kinds of platforms and expression data types. Our model showed a robust prediction not only in bladder cancer, but also in other pan-cancer types.

Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer

Does Selected Immunological Panel Possess the Value of Predicting the Prognosis of Early-Stage Resectable Non-Small Cell Lung Cancer?

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

A four‐gene signature predicts the efficacy of paclitaxel‐based neoadjuvant therapy in human epidermal growth factor receptor 2–negative breast cancer

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Machine Learning Identifies Immune-Based Biomarkers That Predict Efficacy of Anti-Angiogenesis-based Therapies in Advanced Lung Cancer

A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer

Identification of A 10-Gene Signature to Predict Efficacy of Neoadjuvant Therapy in Patients with HER2 Positive Breast Cancer.

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients

Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer

Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study

Correlation Between Immune-Related Genes and Tumor-Infiltrating Immune Cells With the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

Immune Effective Score As A Predictor of Response to Neoadjuvant Trastuzumab Therapy and A Prognostic Indicator for HER2-positive Breast Cancer

Combination of Immune-Related Network and Subtype-Specific Analysis Define a Three- Gene Panel for Predicting Prognosis of Triple-Negative Breast Cancer

Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.

Identifies Immune Feature Genes for Prediction of Chemotherapy Benefit in Cancer

Prediction of Immunotherapy Response by Integrating Immune Infiltration and Neoantigen Presentation Score in Late-Stage Melanoma.

Elevated Levels of Neutrophil Related Chemokine Citrullinated Histone H3, Interleukin-8 and C-reaction Protein in Patients with Immune Checkpoint Inhibitor Therapy: Predictive Biomarkers for Response to Treatment

Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio